Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | CASP3 | P42574 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.73 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.73 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 1/20 | 0.72 |
| ▸ | CDK2 | P24941 | 1/20 | 0.72 |
| ▸ | GSK3B | P49841 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27861124 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL7261477 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL4600722 | 0.84 | AURKA (1.00) | SMN1; SMN2MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL4912447 | 0.84 | MAPT (0.72) | SMN1; SMN2MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL31238157 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL7690800 | 0.80 | MAPT (0.78) | SMN1; SMN2MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL17199017 | 0.80 | KDM4E (0.80) | SMN1; SMN2MAPTMEN1KMT2ATP53 | |
| SCHEMBL28010665 | 0.80 | MAPT (0.69) | SMN1; SMN2MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL6465664 | 0.80 | ALDH1A1 (0.66) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL3223685 | 0.79 | RAB9A (1.00) | SMN1; SMN2MAPTMEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | SMN1; SMN2 3410/4885MAPT 2771/4885MEN1 1437/4885 |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | SMN1; SMN2 3931/4885MAPT 4151/4885MEN1 4843/4885 |
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | SMN1; SMN2 3410/4885MAPT 2771/4885MEN1 1437/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | SMN1; SMN2 3410/4885MAPT 2771/4885MEN1 1437/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | SMN1; SMN2 3931/4885MAPT 4151/4885MEN1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.